S. Oostindie

发表

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

E. M. Cook, P. Parren, J. Schuurman, 2016, The Journal of Immunology.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

E. M. Cook, P. Parren, K. Vandermeid, 2019, Haematologica.

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

P. Parren, Laurens P. Kil, B. van Kessel, 2020, Blood Cancer Journal.

Avidity in antibody effector functions and biotherapeutic drug design

G. A. Lazar, P. Parren, G. Lazar, 2022, Nature Reviews Drug Discovery.

Carbamylation reduces the capacity of IgG for hexamerization and complement activation

P. Parren, T. Sharp, L. Trouw, 2019, Clinical and experimental immunology.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

P. Parren, A. Heck, S. Verploegen, 2016, PLoS biology.

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

P. Parren, S. Verploegen, A. Labrijn, 2020, EBioMedicine.

Logic-gated antibody pairs that selectively act on cells co-expressing two antigens

M. Wester, S. Verploegen, D. Lidke, 2022, Nature Biotechnology.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

E. M. Cook, P. Parren, J. Schuurman, 2016, The Journal of Immunology.

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

T. Mutis, S. Zweegman, Hilma J. van der Horst, 2020, HemaSphere.

Cyton2: A Model of Immune Cell Population Dynamics That Includes Familial Instructional Inheritance

P. Hodgkin, S. Heinzel, S. Dovedi, 2021, Frontiers in Bioinformatics.